Science misinformation alarms Francis Collins as he leaves top NIH job
By Nidhi Subbaraman,
Nature
| 12. 03. 2021
The genome project leader reflects on his 12 years at the helm of a juggernaut biomedical agency, and what lies ahead.
This month, Francis Collins will step down as director of the US National Institutes of Health (NIH) after more than 12 years leading the agency, the world’s biggest public funder of biomedical research. A former head of the Human Genome Project, he championed similar bold, big-budget science efforts, such as the All of Us Project, which aims to study health data from one million people. He led the NIH under three US presidents, steered it through a roiling pandemic, and faced myriad clashes over politics and biomedical science. Collins will stay on at the NIH to continue research in his lab. He spoke to Nature about some highlights of his time at the helm, and issues facing the agency in the future.
Which achievement will you cherish most?
It’s really hard to pick one. Maybe it’s where it was possible to bring together scientists of multiple disciplines and organize a truly bold, audacious project that would simply not have happened if one just counted on it coming together passively. I’m thinking of the BRAIN Initiative. I’m thinking of what...
Related Articles
By Rob Stein, NPR [cites CGS' Katie Hasson] | 08.06.2025
A Chinese scientist horrified the world in 2018 when he revealed he had secretly engineered the birth of the world's first gene-edited babies.
His work was reviled as reckless and unethical because, among other reasons, gene-editing was so new...
By Kristel Tjandra, Genetic Engineering & Biotechnology News | 07.30.2025
CRISPR has taken the bioengineering world by storm since its first introduction. From treating sickle cell diseases to creating disease-resistant crops, the technology continues to boast success on various fronts. But getting CRISPR experiments right in the lab isn’t simple...
By Arthur Caplan and James Tabery, Scientific American | 07.28.2025
An understandable ethics outcry greeted the June announcement of a software platform that offers aspiring parents “genetic optimization” of their embryos. Touted by Nucleus Genomics’ CEO Kian Sadeghi, the $5,999 service, dubbed “Nucleus Embryo,” promised optimization of...
By Keith Casebonne and Jodi Beckstine [with CGS' Katie Hasson], Disability Deep Dive | 07.24.2025
In this episode of Disability Deep Dive, hosts Keith and Jodi explore the complex interplay between disability science, technology, and ethics with guest Katie Hasson, Associate Director at the Center for Genetics and Society. The conversation delves into...